Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 432

1.

Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.

Vianello F, Papeta N, Chen T, Kraft P, White N, Hart WK, Kircher MF, Swart E, Rhee S, Palù G, Irimia D, Toner M, Weissleder R, Poznansky MC.

J Immunol. 2006 Mar 1;176(5):2902-14. Erratum in: J Immunol. 2006 May 1;176(9):5683.

2.

CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture.

Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ, Putt M, Gimotty P, Swoboda R, Herlyn M, Herlyn D.

J Immunol. 2005 May 1;174(9):5856-63.

3.

Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.

Lee CH, Kakinuma T, Wang J, Zhang H, Palmer DC, Restifo NP, Hwang ST.

Mol Cancer Ther. 2006 Oct;5(10):2592-9.

5.

A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.

Xie Y, Wang L, Freywald A, Qureshi M, Chen Y, Xiang J.

Cell Mol Immunol. 2013 Jan;10(1):72-7. doi: 10.1038/cmi.2012.37. Epub 2012 Oct 8.

6.

T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.

Quatromoni JG, Morris LF, Donahue TR, Wang Y, McBride W, Chatila T, Economou JS.

J Hematol Oncol. 2011 Nov 23;4:48. doi: 10.1186/1756-8722-4-48.

7.
8.

Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.

Prévost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, Pircher H.

J Immunol. 1998 Sep 1;161(5):2187-94.

9.

Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells.

Zhang T, Somasundaram R, Berking C, Caputo L, Van Belle P, Elder D, Czerniecki B, Hotz S, Schuchter L, Spitz FR, Berencsi K, Rani P, Marincola F, Qiu R, Herlyn D.

Cancer Biol Ther. 2006 Oct;5(10):1304-12. Epub 2006 Oct 4.

PMID:
16929176
10.
11.

Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.

Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, Garancini MP, Casorati G, Dellabona P.

J Immunol. 2000 Sep 1;165(5):2651-6.

12.
13.

A CXCR4-dependent chemorepellent signal contributes to the emigration of mature single-positive CD4 cells from the fetal thymus.

Vianello F, Kraft P, Mok YT, Hart WK, White N, Poznansky MC.

J Immunol. 2005 Oct 15;175(8):5115-25.

14.

CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity.

Zhang H, Xie Y, Li W, Chibbar R, Xiong S, Xiang J.

Cell Mol Immunol. 2011 Jan;8(1):23-30. doi: 10.1038/cmi.2010.59. Epub 2010 Dec 13.

15.

Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells.

Murakami T, Maki W, Cardones AR, Fang H, Tun Kyi A, Nestle FO, Hwang ST.

Cancer Res. 2002 Dec 15;62(24):7328-34.

16.

USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.

Hong B, Li H, Lu Y, Zhang M, Zheng Y, Qian J, Yi Q.

Mol Cancer. 2014 May 31;13:132. doi: 10.1186/1476-4598-13-132.

17.

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM.

J Immunol. 2005 Jun 15;174(12):7516-23.

18.

Long-term survival of transplanted allogeneic cells engineered to express a T cell chemorepellent.

Papeta N, Chen T, Vianello F, Gererty L, Malik A, Mok YT, Tharp WG, Bagley J, Zhao G, Stevceva L, Yoon V, Sykes M, Sachs D, Iacomini J, Poznansky MC.

Transplantation. 2007 Jan 27;83(2):174-83.

PMID:
17264814
19.
20.

Supplemental Content

Support Center